Entity

Time filter

Source Type


Trademark
PIRAMAL HEALTHCARE CANADA Ltd, Bio Syntech Canada Inc. and Bio Syntech Ltee | Date: 2005-11-29

Topical liquid gel for medical and surgical use in the treatment of traumatic injuries to the joints and diseases of the joints.


Trademark
Biomomentum Inc., PIRAMAL HEALTHCARE CANADA Ltd, Bio Syntech Canada Inc. and Bio Syntech Ltee | Date: 2005-11-29

Arthroscopic instrument, namely, to monitor cartilage health.


Trademark
Piramal Healthcare Canada Ltd | Date: 2001-05-15

topical liquid gel for medical and surgical use in the treatment of traumatic injuries to the joints and diseases of the joints.


Patent
Piramal Healthcare Canada Ltd. | Date: 2015-12-17

The present invention relates to a minimally-invasive method for restoring a damaged or degenerated intevertebral disc at an early stage. The method comprises the step of administering an injectable in situ setting formulation in the nucleus pulposus of the damaged or degenerated disc of the patient. The formulation once injected combines with nucleus matters and host cells, and becomes viscous or gels in situ within the annulus fibrosus of the disc for increasing the thickness and volume of the damaged or degenerated disc. The formulation is retained within the disc for providing restoration of the damaged or degenerated disc.


Shive M.S.,Piramal Healthcare Canada Ltd | Restrepo A.,Piramal Healthcare Canada Ltd | Totterman S.,Qmetrics Technologies | Tamez-Pena J.,Monterrey Institute of Technology | And 3 more authors.
Osteoarthritis and Cartilage | Year: 2014

Objective: Intra-lesional bony overgrowth (BO) identified during or following cartilage repair treatment is being frequently described through subjective reports focusing primarily on incidence. Our objective was to quantify the exact volume of intra-lesional BO at 12 months post-cartilage repair treatment, to determine if a correlation exists between the extent of BO and clinical outcomes, and to visualize and characterize the BO. Design: MRI scans were systematically obtained during a randomized clinical trial for cartilage repair (Stanish etal., 2013) that compared two microfracture-based treatments in 78 patients. Semi-automated morphological segmentation of pre-treatment, 1 and 12 months post-treatment scans utilizing a programmed anatomical atlas for all knee bone and cartilage structures permitted three-dimensional reconstruction, quantitative analysis, as well as qualitative characterization and artistic visualization ofBO. Results: Limited intra-lesional BO representing only 5.8±5.7% of the original debrided cartilage lesion volume was found in 78 patients with available MRIs at 12 months. The majority (80%) of patients had very little BO (<10%). Most occurrences of BO carried either spotty (56.4%) or planar (6.4%) morphological features, and the remaining balance (37.2%) was qualitatively unobservable by eye. Pre-existing BO recurred at 12 months in the same intra-lesional location in 36% of patients. No statistical correlations were found between BO and clinical outcomes. Conclusions: Intra-lesional BO following microfracture-based treatments may not be as severe as previously believed, its incidence is partly explained by pre-existing conditions, and no relationship to clinical outcomes exists at 12 months. Morphologically, observable BO was categorized as comprising either spotty or planar bone. © 2014 Osteoarthritis Research Society International.

Discover hidden collaborations